RxDoctor Payments Data

Maria Weimer

Neurology with Special Qualifications in Child Neurology · New Orleans, LANPI 1659394518

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 239 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 14.8% — the pattern of someone who eats at a lot of different presentations.

$5,772in general payments, 2019–2025

Across 239 payments — averaging $24.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$855
  • Eisai Inc.$435
  • SK Life Science, Inc.$411
  • Neurelis, Inc.$394
  • Jazz Pharmaceuticals Inc.$391
  • Supernus Pharmaceuticals, Inc.$367
  • plus $3K from 31 others

What the payments were for

  • Food & beverage$5,772100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,772 in reported general payments places this provider in the 55th percentile of 30 neurology with special qualifications in child neurology providers in Louisiana.

See all neurology with special qualifications in child neurology providers in Louisiana

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxtellar XrOxcarbazepine14$32,785

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Supernus Pharmaceuticals, Inc.Oxtellar Xr$367$32,78514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 30 neurology with special qualifications in child neurology providers in Louisiana.

Other neurology with special qualifications in child neurology in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →